Clinical Trials Browser

Phase 2/3 × Endometrial Neoplasms × Clear all

NCT05255653 2026-05-15

RAINBO

Phase 2/3 Recruiting

Endometrial Neoplasms

NCT07319429 2026-03-13

FEMUS

Phase 2/3 Recruiting

Endometrial Neoplasms

NCT05454358 2025-12-15

Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP

Phase 2/3 Terminated

Endometrial Neoplasms

NCT06851663 2025-12-08

Trop2-targeted immunoPET Imaging of Solid Tumors

Phase 2/3 Recruiting

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Nasopharyngeal Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Thyroid Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT05770102 2025-11-24

DETERMINE

Phase 2/3 Recruiting

DermatologicGastrointestinalGynecologicLymphoid

Lymphoproliferative Disorders, Melanoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Colorectal Neoplasms, Endometrial Neoplasms

NCT06321068 2025-08-14

BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

Phase 2/3 Terminated

Endometrial Neoplasms

NCT04159155 2025-08-12

CAN-STAMP

Phase 2/3 Terminated

Endometrial Neoplasms, Cystadenocarcinoma, Serous

NCT05316467 2025-08-11

Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma

Phase 2/3 Recruiting

GynecologicOther

Infertility, Obesity, Endometrial Neoplasms, Overweight

NCT05316935 2025-08-11

GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

Phase 2/3 Recruiting

Progesterone Resistance, Endometrial Hyperplasia, Endometrial Neoplasms

NCT06379113 2025-08-11

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

Phase 2/3 Recruiting

GynecologicOther

Progesterone Resistance, Endometrial Hyperplasia, Obesity, Endometrial Neoplasms

NCT05797831 2024-05-02

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Phase 2/3 Recruiting

Endometrial Neoplasms

NCT05489848 2022-08-05

Chemotherapy vs Chemoradiotherapy for Post-operative Endometrial Cancer Patients With P53-mutation

Phase 2/3 Not yet recruiting

Endometrial Neoplasms

NCT03463252 2021-09-13

Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC

Phase 2/3 Recruiting

Endometrial Hyperplasia, Endometrial Neoplasms

NCT03241914 2020-11-20

Megestrol Acetate Plus LNG-IUS in Young Women With Early Endometrial Cancer

Phase 2/3 Completed

Endometrial Neoplasms